-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Search results for: “patient perspective”
-
Role of Thai Oncology Pharmacists in Lung Cancer Treatment: A Q&A With Dr. Suthan Chanthawong
Suthan Chanthawong, BPharm, BCP, BCOP, is an assistant professor of Pharmaceutical Sciences in the Division of Clinical Pharmacy at Khon Kaen University, in Thailand. In the following interview, he discusses how oncology pharmacists differ from other pharmacists in his region, as well as the role they play in supporting decision making to balance the cost…
-
Research’s Race to Stop a Pandemic
Experts discuss how a global pandemic is putting pressure on traditional methods of research dissemination. A search on PubMed.gov for COVID-19 reveals 93,851 results as of Mid-January 2021. “To put that in perspective, if I search for EGFR, a major area of cancer research, there are just over 96,000 results in the 40 years since…
-
Impactful Multidisciplinary Care Not Out of Reach in Community Settings
In 2014 the IASLC, in collaboration with the American Thoracic Society and the European Respiratory Society, published a new classification of lung adenocarcinoma.1 The publication addressed new terminology and diagnostic criteria for lung adenocarcinoma, but it also highlighted “the importance of a close collaboration between oncologist, pathologist, molecular biologist, radiologist and surgeons … to offer…
-
Interstitial Lung Abnormality, Interstitial Lung Disease, and Lung Cancer
As a practicing chest radiologist in Boston, one of this article’s authors (Dr. Hatabu) encounters several patients with drug-related pneumonitis (DRP) daily when on clinical duty. Sometimes DRP coexists with COVID-19 pneumonia or radiation pneumonitis. Recently, clinicians have begun to notice the increased incidence of DRP associated with molecular targeted therapy and immunotherapy in patients…
-
Growing Importance and Changing Dynamics: Social Media’s Ever-Changing Role in Thoracic Oncology
Although some resist its gravitational pull, social media and especially Twitter are becoming an increasingly valuable tool in academic and community-based cancer care, with thoracic oncology helping set the pace for its growing presence. As its utility continues to grow, social media has been forging a stronger international community that is no longer limited by…
-
Decade in Review: Changes in Smoking Behaviors Are Altering the Clinical Picture of Lung Cancer
Lung cancer still holds the top position worldwide in terms of the number of new cases and deaths each year, which in 2018 reached 2.1 million and 1.8 million, respectively.1 Given that roughly 85% of all lung cancers can be traced to cigarette smoking, many countries have sought to rein in the morbidity and mortality of the disease by implementing public health initiatives and…
-
Experts Discuss Benefits, Challenges with Lung Cancer Screening: A Pro/Con
Using LDCT to Boost Lung Cancer Prevention Strategies: A Pro/Con By Ugo Pastorino, MD Now we know from robust randomized trials that systematic screening with low-dose computed tomography (LDCT) of the chest can reduce lung cancer mortality in heavy smokers by increasing the proportion of cases detected in an early stage,1,2 when they are amenable…
-
Lung Cancer Health Care Delivery, Community Building, and Research: Are They Truly Inclusive?
Lung cancer was first identified as a distinct disease in 1761.1 Since this discovery, we have come a long way—both in terms of progress towards understanding the heterogeneous biology of the disease and translating this understanding into action by development of new treatments.2 Indeed, since 2015, the United States Food and Drug Administration (FDA) has…
-
Dr. Kazuhiko Nakagawa Discusses RELAY Study Data, Implications for Practice
Kazuhiko Nakagawa, MD, PhD, is a professor in the Department of Medical Oncology, Kindai University, Faculty of Medicine, in Japan, and he served as the lead principal investigator on the RELAY study, which investigated ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced NSCLC.1 In the following interview, Dr. Nakagawa discusses the trial’s results, as…
-
Ending Stigma in Lung Cancer: The IASLC Participates in a Collaborative Summit Held by the National Lung Cancer Roundtable
Stigma is any thinking or behavior that produces internal shame or external judgment toward a person, place, or thing.1 In healthcare, stigma could be any sociocultural norm that prevents a patient’s access to or experience of high-quality care. With lung cancer in particular, patients often feel stigmatized by clinicians, patients, family, friends, and within themselves…
View ILCN Archives
Provider Resources
Popular Articles